IGF2R
Overview
IGF2R (Insulin-like Growth Factor 2 Receptor; also mannose-6-phosphate receptor, M6PR) functions as a decoy receptor that sequesters IGF2 and targets it for lysosomal degradation, acting as a negative regulator of IGF signaling. In hepatocellular carcinoma (HCC), allelic loss of IGF2R is observed in ~25% of cases, contributing to elevated IGF2 bioavailability and IGF axis activation.
Alterations observed in the corpus
- ~25% allelic loss of IGF2R in HCC; part of the IGF axis (with ~10% IGF2 overexpression and ~21% IGF1R activation) implicated as a therapeutic target in HCC PMID:24735922
- IGF2R is listed among recurrently mutated genes in the HCC WES landscape (n=1,289), as part of the broader mutational characterization of the IGF signaling axis. PMID:24798001
Cancer types (linked)
- HCC — allelic loss in ~25% of HCC, contributing to IGF axis hyperactivation PMID:24735922
Co-occurrence and mutual exclusivity
- Co-occurs with IGF2 overexpression (~10%) and IGF1R activation (~21%) as components of a deregulated IGF axis in HCC PMID:24735922
Therapeutic relevance
- IGF axis targeting (via IGF1R inhibitors) is a therapeutic strategy in HCC; IGF2R allelic loss contributes to the mechanistic rationale PMID:24735922
Open questions
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:24798001
This page was processed by entity-page-writer on 2026-05-11.